Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
Emyria LtdTelephone
61.13.0043.6363
Address
D2 661 Newcastle Street Leederville, Western Australia (WA) 6007
Description
Emyria Ltd. is a healthcare technology and services company. It operates a network of specialist medical clinics and uses purpose-built software and technology to gather clinical data from informed and consenting patients. The company was founded on March 19, 2018 and is headquartered in Leederville, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.03 - 0.08
Trade Value (12mth)
AU$4,099.00
1 week
-11.63%
1 month
18.75%
YTD
-30.91%
1 year
-33.33%
All time high
0.50
EPS 3 yr Growth
43.00%
EBITDA Margin
-281.80%
Operating Cashflow
-$4m
Free Cash Flow Return
-85.30%
ROIC
-228.10%
Interest Coverage
-24.50
Quick Ratio
0.90
Shares on Issue (Fully Dilluted)
409m
HALO Sector
Technology
Next Company Report Date
02-Sep-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
12 December 24 |
Application for quotation of securities - EMD
×
Application for quotation of securities - EMD |
12 December 24 |
Section 708A(5)(e) Notice
×
Section 708A(5)(e) Notice |
27 November 24 |
Emyria Secures $2.525M in Strongly Supported Placement
×
Emyria Secures $2.525M in Strongly Supported Placement |
27 November 24 |
Proposed issue of securities - EMD
×
Proposed issue of securities - EMD |
25 November 24 |
Trading Halt
×
Trading Halt |
25 November 24 |
Investor Update - November 2024
×
Investor Update - November 2024 |
15 November 24 |
Notification of cessation of securities - EMD
×
Notification of cessation of securities - EMD |
12 November 24 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
12 November 24 |
Response to ASX Price Query
×
Response to ASX Price Query |
31 October 24 |
Emyria & UWA Partner to License Novel Serotonin Therapies
×
Emyria & UWA Partner to License Novel Serotonin Therapies |
31 October 24 |
Proposed issue of securities - EMD
×
Proposed issue of securities - EMD |
30 October 24 |
September 2024 Quarterly Activities Report and Appendix 4C
×
September 2024 Quarterly Activities Report and Appendix 4C |
28 October 24 |
Emyria Gains Ethics Endorsement for Psilocybin Program
×
Emyria Gains Ethics Endorsement for Psilocybin Program |
11 October 24 |
Annual Report
×
Annual Report |
11 October 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
11 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
11 October 24 |
Letter to Shareholders - Notice of Annual General Meeting
×
Letter to Shareholders - Notice of Annual General Meeting |
23 September 24 |
Change of Director's Interest Notice x 2
×
Change of Director's Interest Notice x 2 |
20 September 24 |
Application for quotation of securities - EMD
×
Application for quotation of securities - EMD |
20 September 24 |
Notification regarding unquoted securities - EMD
×
Notification regarding unquoted securities - EMD |
20 September 24 |
Section 708A(5)(e) Notice
×
Section 708A(5)(e) Notice |
16 September 24 |
2024 Annual General Meeting - Key Dates
×
2024 Annual General Meeting - Key Dates |
06 September 24 |
Hidden Gems Webinar Presentation
×
Hidden Gems Webinar Presentation |
02 September 24 |
Emyria Shares Interim Success in PTSD Treatment Program
×
Emyria Shares Interim Success in PTSD Treatment Program |
30 August 24 |
Appendix 4E & Annual Report for the Year Ended 30 June 2024
×
Appendix 4E & Annual Report for the Year Ended 30 June 2024 |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.